Neuberg Diagnostics has consolidated its Maharashtra operations with NM Medical to build a unified diagnostic network, targeting ₹500 crore in state revenue. This strategic move aligns with the company’s roadmap toward a planned IPO in FY28, following a recent funding round of ₹940 crore. The integration aims to combine advanced genomics with radiology services, strengthening the group's position in the competitive preventive healthcare market.
Neuberg Diagnostics is restructuring its presence in Maharashtra by merging its regional operations with NM Medical. This consolidation creates a comprehensive diagnostic network, blending NM Medical’s established strengths in radiology, cardiology, and preventive screenings with Neuberg’s specialized capabilities in genomics, digital pathology, and molecular diagnostics. The company expects this unified entity to generate approximately ₹500 crore in annual revenue from its Maharashtra business.
The strategic integration is designed to improve patient access by centralizing a wide array of services. Instead of navigating separate facilities for routine tests, imaging, and advanced screenings, patients can now access these services through a consolidated network. For the company, this move allows for better utilization of technical assets and creates opportunities for cross-selling between its diverse service lines.
IPO Roadmap and Financial Context
While Neuberg Diagnostics is a private company and not listed on the NSE or BSE, this operational merger is a significant milestone in its growth strategy. The group is preparing for a potential initial public offering (IPO) in the financial year 2028, with an expected size of ₹3,500 crore to ₹4,000 crore. To support this inorganic growth strategy, the company raised ₹940 crore earlier this year from the Kotak Strategic Situations India Fund II. The firm reported a total revenue of ₹1,400 crore for the financial year 2026, and this latest consolidation is part of its broader push to scale its pan-India operations ahead of the public listing.
Beyond traditional testing, the group is pivoting toward higher-value services. On October 3, 2026, the company launched 'Atlas,' a platform dedicated to longevity and proactive health management. This launch reflects a broader trend in the diagnostic sector, where companies are increasingly moving beyond standard pathology to capture the premium wellness market.
Sector Competition and Execution
The Indian diagnostic sector is highly competitive and fragmented. Many diagnostic chains are aggressively acquiring regional players to expand their network and gain scale. For Neuberg, the path to its IPO depends on the successful integration of its acquired businesses and its ability to maintain profit margins amid this expansion. The company’s reliance on an acquisition-led growth model requires significant capital, making it sensitive to funding conditions. As the company continues its expansion, industry observers will monitor whether these integrations lead to improved efficiency and market share in highly contested regions like Maharashtra.